Meditera Tibbi Malzeme Sanayi ve Ticaret AS
Meditera Tibbi Malzeme Sanayi ve Ticaret Anonim Sirketi manufactures and sells medical devices in Turkey. The company offers breathing sytems products, including breathing circuits, breathing filters, catheter mounts, gas sampling lines, accessories, masks, and connectors. It also provides hospital products, such as barrier cream, surgical hand brushes for skin disinfection, hand and skin antisep… Read more
Meditera Tibbi Malzeme Sanayi ve Ticaret AS (MEDTR) - Net Assets
Latest net assets as of September 2025: TL2.77 Billion TRY
Based on the latest financial reports, Meditera Tibbi Malzeme Sanayi ve Ticaret AS (MEDTR) has net assets worth TL2.77 Billion TRY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (TL3.52 Billion) and total liabilities (TL750.74 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | TL2.77 Billion |
| % of Total Assets | 78.66% |
| Annual Growth Rate | 65.65% |
| 5-Year Change | 929.22% |
| 10-Year Change | N/A |
| Growth Volatility | 58.65 |
Meditera Tibbi Malzeme Sanayi ve Ticaret AS - Net Assets Trend (2018–2024)
This chart illustrates how Meditera Tibbi Malzeme Sanayi ve Ticaret AS's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Meditera Tibbi Malzeme Sanayi ve Ticaret AS (2018–2024)
The table below shows the annual net assets of Meditera Tibbi Malzeme Sanayi ve Ticaret AS from 2018 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | TL2.23 Billion | +4.61% |
| 2023-12-31 | TL2.14 Billion | +140.84% |
| 2022-12-31 | TL887.08 Million | +55.80% |
| 2021-12-31 | TL569.37 Million | +162.20% |
| 2020-12-31 | TL217.15 Million | +71.68% |
| 2019-12-31 | TL126.49 Million | +16.99% |
| 2018-12-31 | TL108.11 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Meditera Tibbi Malzeme Sanayi ve Ticaret AS's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 2069.4% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | TL531.36 Million | 23.83% |
| Other Components | TL1.70 Billion | 76.17% |
| Total Equity | TL2.23 Billion | 100.00% |
Meditera Tibbi Malzeme Sanayi ve Ticaret AS Competitors by Market Cap
The table below lists competitors of Meditera Tibbi Malzeme Sanayi ve Ticaret AS ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
IAMU SA
RO:IAMU
|
$19.51 Million |
|
HAKI Safety A
ST:HAKI-A
|
$19.52 Million |
|
Vidipha Central Pharmaceutical JSC
VN:VDP
|
$19.52 Million |
|
Big Tree Cloud Holdings Limited Ordinary Shares
NASDAQ:DSY
|
$19.52 Million |
|
Ezfly International Travel Agent Co. Ltd.
TWO:2734
|
$19.49 Million |
|
Guangdong Land Holdings Limited
PINK:KYBWF
|
$19.48 Million |
|
Health In Tech, Inc. Class A Common Stock
NASDAQ:HIT
|
$19.48 Million |
|
TOP Engineering Co. Ltd
KQ:065130
|
$19.48 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Meditera Tibbi Malzeme Sanayi ve Ticaret AS's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 2,128,322,568 to 2,229,985,122, a change of 101,662,554 (4.8%).
- Net income of 73,429,958 contributed positively to equity growth.
- Dividend payments of 34,612,882 reduced retained earnings.
- New share issuances of 125,184,019 increased equity.
- Other factors decreased equity by 62,338,541.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | TL73.43 Million | +3.29% |
| Dividends Paid | TL34.61 Million | -1.55% |
| Share Issuances | TL125.18 Million | +5.61% |
| Other Changes | TL-62.34 Million | -2.8% |
| Total Change | TL- | 4.78% |
Book Value vs Market Value Analysis
This analysis compares Meditera Tibbi Malzeme Sanayi ve Ticaret AS's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.51x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 61.44x to 1.51x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | TL0.46 | TL28.24 | x |
| 2019-12-31 | TL0.56 | TL28.24 | x |
| 2020-12-31 | TL1.82 | TL28.24 | x |
| 2021-12-31 | TL4.78 | TL28.24 | x |
| 2022-12-31 | TL7.44 | TL28.24 | x |
| 2023-12-31 | TL18.09 | TL28.24 | x |
| 2024-12-31 | TL18.74 | TL28.24 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Meditera Tibbi Malzeme Sanayi ve Ticaret AS utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 3.29%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 3.51%
- • Asset Turnover: 0.75x
- • Equity Multiplier: 1.26x
- Recent ROE (3.29%) is below the historical average (19.67%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 22.83% | 6.26% | 0.98x | 3.72x | TL7.02 Million |
| 2019 | 18.97% | 5.49% | 1.05x | 3.28x | TL6.02 Million |
| 2020 | 27.83% | 16.82% | 1.05x | 1.57x | TL38.71 Million |
| 2021 | 29.45% | 44.61% | 0.52x | 1.26x | TL110.76 Million |
| 2022 | 33.54% | 36.85% | 0.73x | 1.24x | TL208.48 Million |
| 2023 | 1.75% | 1.78% | 0.77x | 1.28x | TL-175.49 Million |
| 2024 | 3.29% | 3.51% | 0.75x | 1.26x | TL-149.57 Million |
Industry Comparison
This section compares Meditera Tibbi Malzeme Sanayi ve Ticaret AS's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $42,775,873
- Average return on equity (ROE) among peers: 16.87%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Meditera Tibbi Malzeme Sanayi ve Ticaret AS (MEDTR) | TL2.77 Billion | 22.83% | 0.27x | $19.51 Million |
| Anatolia Tani ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi ve Ticaret (ANGEN) | $9.53 Million | 9.06% | 1.07x | $11.89 Million |
| Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. (ONCSM) | $76.02 Million | 24.69% | 0.74x | $30.36 Million |